245 results
Page 2 of 13
8-K
EX-99.1
lq41v0at1rbehs7aahsk
28 Apr 23
Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
8:30am
8-K
EX-99.1
8ks zeqf001p9
8 Nov 22
Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update
8:55am
8-K
EX-99.1
a0q 5h1wq6
15 Aug 22
Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update
8:05am
8-K
EX-10.1
k0tj ubc7ambax6xo89
21 Jun 22
Departure of Directors or Certain Officers
7:31am
8-K
EX-10.2
az9ttt vg2
21 Jun 22
Departure of Directors or Certain Officers
7:31am
8-K
EX-99.1
0fx4saatvi24iafumu
9 Jun 22
Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance
8:08am
424B3
nsirugp1
27 May 22
Prospectus supplement
9:01am
8-K
EX-99.1
6vvn3i i6g
26 May 22
Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting
5:06pm
8-K
EX-99.1
25zk1hhfy4
13 May 22
Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights
8:03am
D
nhh845g2
11 May 22
$15M in equity / options / securities to be acquired, sold $15M, 2 investors
3:42pm
8-K
EX-99.1
x8j3jqt csq8
2 May 22
Tempest Announces Private Placement Financing of $15 Million
8:02am
8-K
EX-10.1
rco8vbsc7n7
2 May 22
Tempest Announces Private Placement Financing of $15 Million
8:02am
8-K
EX-10.2
bep45k7jy
2 May 22
Tempest Announces Private Placement Financing of $15 Million
8:02am
PRE 14A
q3pvh3bsmyd8t3mxny0
22 Apr 22
Preliminary proxy
4:01pm